Baseline characteristics of the replication cohort (WARG)
| Total number of genotyped patients . | 1496 . |
|---|---|
| Age, y | 66 (57;74) |
| Sex, male/female | 947 (63%)/549 (37%) |
| Indication for warfarin treatment | |
| Atrial fibrillation | 762 (51%) |
| Deep venous thrombosis | 378 (25%) |
| Pulmonary embolism | 188 (13%) |
| Heart valve transplant, artificial | 34 (2.3%) |
| Cerebral infarction/transient ischemic attack | 28 (1.9%) |
| Heart valve transplant, biologic | 25 (1.7%) |
| Cardiomyopathy/cardiac failure | 23 (1.5%) |
| Other indications* | 58 (3.9%) |
| Planned treatment duration | |
| Less than 3 mo | 13 (0.9%) |
| 3-5 mo | 214 (14%) |
| 6-12 mo | 387 (26%) |
| More than 12 mo, specified | 14 (0.9%) |
| Infinite or not predefined | 868 (58%) |
| Warfarin induction, mg | |
| First dose | 10 (1.25;15) |
| Second dose | 7.5 (1.25;15) |
| Third dose | 5.0 (1.25;10) |
| INR, international normalized ratio | |
| Lower limit of therapeutic interval | 2.1 (1.5;3.1) |
| Target value | 2.5 (1.8;3.0) |
| Upper limit of therapeutic interval | 3.0 (2.0;3.6) |
| Percent of time within therapeutic INR interval | 63.8 (50.9;73.5) |
| Patients experiencing bleeding events | |
| Serious bleeding | 28 (1.9%) |
| All bleeding | 146 (9.8%) |
| Comedication, number of drugs | 2 (0;18) |
| Patients using drugs that interact with warfarin† | |
| No interacting drug | 781 (52%) |
| Drugs decreasing warfarin effect | 56 (3.7%) |
| Drugs potentiating warfarin effect (reflected in INR) | 691 (46%) |
| Genotypes of VKORC1‡ and CYP2C9§ | |
| VKORC1 rs9923231 (−1639) G/G | 529 (36%) |
| VKORC1 rs9923231 (−1639) A/G | 714 (49%) |
| VKORC1 rs9923231 (−1639) A/A | 218 (15%) |
| CYP2C9*1/*1 | 988 (66%) |
| CYP2C9*1/*2 | 277 (19%) |
| CYP2C9*1/*3 | 177 (12%) |
| CYP2C9*2/*2 | 21 (1.4%) |
| CYP2C9*2/*3 | 19 (1.3%) |
| CYP2C9*3/*3 | 8 (0.5%) |
| Total number of genotyped patients . | 1496 . |
|---|---|
| Age, y | 66 (57;74) |
| Sex, male/female | 947 (63%)/549 (37%) |
| Indication for warfarin treatment | |
| Atrial fibrillation | 762 (51%) |
| Deep venous thrombosis | 378 (25%) |
| Pulmonary embolism | 188 (13%) |
| Heart valve transplant, artificial | 34 (2.3%) |
| Cerebral infarction/transient ischemic attack | 28 (1.9%) |
| Heart valve transplant, biologic | 25 (1.7%) |
| Cardiomyopathy/cardiac failure | 23 (1.5%) |
| Other indications* | 58 (3.9%) |
| Planned treatment duration | |
| Less than 3 mo | 13 (0.9%) |
| 3-5 mo | 214 (14%) |
| 6-12 mo | 387 (26%) |
| More than 12 mo, specified | 14 (0.9%) |
| Infinite or not predefined | 868 (58%) |
| Warfarin induction, mg | |
| First dose | 10 (1.25;15) |
| Second dose | 7.5 (1.25;15) |
| Third dose | 5.0 (1.25;10) |
| INR, international normalized ratio | |
| Lower limit of therapeutic interval | 2.1 (1.5;3.1) |
| Target value | 2.5 (1.8;3.0) |
| Upper limit of therapeutic interval | 3.0 (2.0;3.6) |
| Percent of time within therapeutic INR interval | 63.8 (50.9;73.5) |
| Patients experiencing bleeding events | |
| Serious bleeding | 28 (1.9%) |
| All bleeding | 146 (9.8%) |
| Comedication, number of drugs | 2 (0;18) |
| Patients using drugs that interact with warfarin† | |
| No interacting drug | 781 (52%) |
| Drugs decreasing warfarin effect | 56 (3.7%) |
| Drugs potentiating warfarin effect (reflected in INR) | 691 (46%) |
| Genotypes of VKORC1‡ and CYP2C9§ | |
| VKORC1 rs9923231 (−1639) G/G | 529 (36%) |
| VKORC1 rs9923231 (−1639) A/G | 714 (49%) |
| VKORC1 rs9923231 (−1639) A/A | 218 (15%) |
| CYP2C9*1/*1 | 988 (66%) |
| CYP2C9*1/*2 | 277 (19%) |
| CYP2C9*1/*3 | 177 (12%) |
| CYP2C9*2/*2 | 21 (1.4%) |
| CYP2C9*2/*3 | 19 (1.3%) |
| CYP2C9*3/*3 | 8 (0.5%) |
Age and time within therapeutic INR interval are presented as median (interquartile range). Other parameters are presented as median (range) or number of patients (percent).
Includes carotid dissection and stenosis, unspecified cardiac embolism, myocardial infarction, peripheral artery disease, sinus thrombosis, and cardiac arrhythmias other than atrial fibrillation.
Drugs that interact without affecting INR are not presented here. Some patients have drugs that both increase and decrease INR.
VKORC1 rs9923231 genotypes are missing in 35 patients.
CYP2C9 genotyping results from *2 and *3 alleles are missing in 6 patients.